New obesity drug AMG 133 passes early safety check in 110 people
NCT ID NCT04478708
First seen Jan 05, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This early-stage study tested a new drug called AMG 133 in 110 adults with obesity. The main goal was to see if the drug is safe and how the body processes it. Participants received either the drug or a placebo, and researchers tracked side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Anaheim Clinical Trials
Anaheim, California, 92801, United States
-
Clinical Pharmacology of Miami, LLC
Miami, Florida, 33014, United States
-
Orange County Research Center
Tustin, California, 92780, United States
Conditions
Explore the condition pages connected to this study.